Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of mRNA-1189 EBV Vaccine in Healthy Adults
NCT07478952Phase 1Recruiting
- Sponsor
- Moderna Inc
- Start
- Mar 2026
- Primary completion
- May 2027
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of mRNA-1189 in Epstein-Barr virus infection (4 arms), sponsored by Moderna Inc. Primary endpoints: Number of Participants with Solicited Local and Systemic Adverse Reactions at Day 64, Number of Participants with Unsolicited Adverse Events at Day 85 and 2 more. Started Mar 2026; status: recruiting.
02
Drugs
mRNA-1189
03
Conditions
Epstein-Barr virus infection
Beyond the preview
Go deeper on NCT07478952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07478952.